Poster
A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)
Author
Alexander Spira
Condition
non-small cell lung cancer (NSCLC)
Drug target
EGFR
Drug moa
EGFR inhibitor
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-ASCO-2022-BLU-701-EGFR-Lung-Cancer-Poster.pdf
1 organization
1 product
Product
BLU-701Organization
Blueprint Medicines